Previous 10 | Next 10 |
The USPTO has granted two composition of matter patents for Compugen's (NASDAQ: CGEN ) COM701, lead immuno-oncology therapeutic antibody candidate. More news on: Compugen Ltd., Healthcare stocks news, Read more ...
HOLON, Israel , March 12, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter ...
HOLON, Israel , March 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that John Hunter , PhD, Chief Scientific Officer, will present a corporate o...
HOLON, Israel , March 1, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, ...
Compugen Ltd. (CGEN) Q4 2018 Earnings Conference Call February 26, 2019 8:30 a.m. ET Company Participants Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Ari Krashin - CFO and COO Henry Adewoye - CMO Conference Call Participants...
Compugen ( CGEN +0.3% ) Q4 results : Revenues: $0; R&D Expense: $7.5M (+4.2%); SG&A: $2.2M (-0.5%). More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
Compugen (NASDAQ: CGEN ): Q4 GAAP EPS of -$0.16 beats by $0.04. More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLON, Israel , Feb. 26, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the fourth quarter and full year ended December 31, 2018 . Compuge...
Noteworthy events during the week of February 24 - March 2 for healthcare investors. More news on: uniQure N.V., Bausch Health Companies Inc., CytomX Therapeutics, Healthcare stocks news, , Read more ...
HOLON, Israel , Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, Februa...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...